ROCA Test for Ovarian Cancer

A simple blood test

The ROCA Test is a blood test that determines the risk of a woman having ovarian cancer.

The test is intended for women with a mutation in the BRCA1 or BRCA2 gene that confers a high risk of developing ovarian cancer.
Women with a BRCA1 or BRCA2 gene mutation are generally recommended to consider surgical removal of their ovaries and fallopian tubes. However, this results in early menopause and affects fertility. Hence many women choose to delay this procedure.

Evaluated in Major Clinical Trials

The ROCA Test has been clinically evaluated in several prospective trials. More information can be found here.

Read our ROCA Test Frequently Asked Questions


Disclaimer: Interpretation of the ROCA Test results is based upon outcomes data from clinical trials. The ROCA Test can detect 95% of ovarian cancers if a patient meets the eligibility criteria listed above and when used in the same multimodal strategy as in the clinical trials. If a patient falls outside of the eligibility criteria, Abcodia cannot guarantee the test results. Any clinical assessment and determination of a course of treatment is solely the responsibility of a patient’s doctor. Abcodia does not offer or provide medical judgment. It is recommended that all ROCA Test results be reviewed by a patient with her doctor.

References:

  1. Cancer Research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer. Last accessed January 2021.